Company intelligence / Profile preview

New Wave Holdings

Ownership: Private
Development stage: Other

Overview

New Wave Holdings is an investment issuer focused on psychedelic compounds and functional mushroom product lines, including psilocybin, LSD, MDMA and ketamine‑derived treatments for neuropsychiatric diseases, but it does not appear to run its own clinical trials or maintain a proprietary therapeutic pipeline.[1][5]

Therapeutic areas: Neurology
Industry: Investors

Beyond the preview

Go deeper on New Wave Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Wave Holdings.

Explore the full profile